niacinamide has been researched along with Carcinoma, Squamous Cell in 105 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 8.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 7.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 7.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "The morbidity and mortality of esophageal cancer is one of the highest around the world and the principal therapeutic method is radiation." | 5.46 | Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. ( Guo, Z; Kuang, Z; Tan, G; Wei, Q; Wu, X; Yang, G; Yang, S; Zhang, J, 2017) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 5.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 4.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 3.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 3.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "In both laryngeal squamous cell carcinoma xenograft tumour lines carbogen was very effective in reducing diffusion limited hypoxia." | 3.70 | Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. ( Bussink, J; Hodgkiss, RJ; Kaanders, JH; Marres, HA; Peters, JP; Rijken, PF; van der Kogel, AJ, 1999) |
| "Sorafenib was administered orally at 400 mg bid on a continuous basis." | 2.82 | Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. ( Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M, 2016) |
| "Sorafenib was administered daily for 7 days before the start of standard RTCT in patients with early-stage, low-risk disease and also during RTCT in patients with high-risk disease." | 2.82 | Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. ( Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I, 2016) |
| "Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are common cancers that are caused principally by ultraviolet (UV) radiation." | 2.80 | A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. ( Chen, AC; Chinniah, N; Choy, B; Dalziell, RA; Damian, DL; Dhillon, HM; Fernández-Peñas, P; Halliday, GM; Kricker, A; Martin, AJ; McKenzie, CA; Scolyer, RA; St George, G; Vardy, JL, 2015) |
| "Patients with cT2-4 squamous cell laryngeal cancer were randomly assigned to AR (68 Gy within 36 to 38 days) or ARCON." | 2.77 | Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. ( Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Marres, HA; Rademakers, SE; Span, PN; Terhaard, CH; van den Ende, P; van der Kogel, AJ, 2012) |
| "Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers." | 2.77 | A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. ( Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA, 2012) |
| "Sorafenib is a small-molecule multitargeted kinase inhibitor that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, vascular endothelial growth factor receptor 2 (VEGFR-2), VEGFR-3 and platelet-derived growth factor receptor β." | 2.76 | Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. ( Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G, 2011) |
| "Sorafenib was well tolerated." | 2.75 | Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. ( Guaglianone, PP; Huang, CH; LeBlanc, M; Moon, J; Urba, SG; Williamson, SK; Wolf, GT, 2010) |
| "Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients." | 2.73 | Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. ( Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E, 2007) |
| "Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B)." | 2.68 | Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report. ( Budihna, M; Furlan, L; Lesnicar, H; Rudolf, Z; Smid, L; Soba, E; Zakotnik, B; Zargi, M, 1995) |
| "The incidence of non-melanoma skin cancer (NMSC) is dramatically increasing worldwide, despite the increased use of improved sunscreens." | 2.61 | Skin cancer prevention: a review of current topical options complementary to sunscreens. ( Chipps, L; Herrmann, J; Rosenthal, A; Stoddard, M, 2019) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "We observed more cases of skin cancer during sorafenib treatment than during sunitinib treatment for advanced RCC; median MKI treatment duration before the identification of skin cancer was longer than 1 year." | 2.49 | Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. ( Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M, 2013) |
| "Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs." | 2.48 | Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. ( Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012) |
| "Sorafenib is a multikinase inhibitor increasingly used for the treatment of several solid tumors." | 1.62 | Penile and scrotal infundibular cysts in an adolescent treated with sorafenib. ( Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A, 2021) |
| "The morbidity and mortality of esophageal cancer is one of the highest around the world and the principal therapeutic method is radiation." | 1.46 | Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. ( Guo, Z; Kuang, Z; Tan, G; Wei, Q; Wu, X; Yang, G; Yang, S; Zhang, J, 2017) |
| "Radioresistance is a common feature of head and neck squamous cell carcinoma (HNSCC)." | 1.46 | Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. ( Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W, 2017) |
| "Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors." | 1.43 | (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016) |
| "In head and neck squamous cell carcinoma (HNSCC), the role of sprouty2 in tumorigenesis and clinical implication remains elusive." | 1.42 | Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL, 2015) |
| "p16-negative HNSCC 11A and 14C cells and p16-positive CERV196 cells were exposed to different concentrations of everolimus, sorafenib and sunitinib for 2-8 days." | 1.42 | Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. ( Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C, 2015) |
| "Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients." | 1.42 | Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. ( Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC, 2015) |
| "Sorafenib was administered orally at 400 mg twice daily on a continuous basis in 28-day cycles to eligible patients." | 1.39 | Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420. ( Banerjee, SK; Hashmi, M; Huang, CH; Leblanc, M; Mehta, S; Moon, J; Rinehart, E; Urba, SG; Williamson, S; Wolf, GT, 2013) |
| "Treatment with sorafenib led to an increased keratinocyte proliferation and a tendency toward increased mitogen-activated protein kinase (MAPK) pathway activation in normal skin." | 1.38 | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. ( André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J, 2012) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of renal cell carcinoma and hepatocellular carcinoma." | 1.37 | [Squamous cell carcinoma in a patient receiving sorafenib]. ( Adnot-Desanlis, L; Bernard, P; Reguiaï, Z, 2011) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 1.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "She had no history of skin cancer." | 1.35 | Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. ( Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ, 2008) |
| "We present a 68-year-old patient with renal cell carcinoma who developed multiple tender hyperkeratotic papules within weeks of starting sorafenib." | 1.35 | The histologic spectrum of epithelial neoplasms induced by sorafenib. ( Jaworsky, C; Kish, LS; Kwon, EJ, 2009) |
| " A novel nicotinamide, AMG 706, was identified as a potent, orally bioavailable inhibitor of the VEGFR1/Flt1, VEGFR2/kinase domain receptor/Flk-1, VEGFR3/Flt4, platelet-derived growth factor receptor, and Kit receptors in preclinical models." | 1.33 | AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. ( Alva, G; Bready, J; Cattley, R; Chen, D; Coxon, A; DeMelfi, T; Diaz, Z; Estrada, J; Gan, Y; Kaufman, S; Kendall, R; Kumar, G; Meyer, J; Montestruque, S; Neervannan, S; Patel, V; Polverino, A; Radinsky, R; Starnes, C; Talvenheimo, J; Tasker, A; Wang, L, 2006) |
| "We used the human hypopharyngeal squamous cell carcinoma cell line FaDu implanted in immune-deficient SCID mice and assessed its response to radiation by cell survival and by growth delay." | 1.30 | Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. ( Brown, JM; Dorie, MJ; el-Said, A; Menke, D, 1999) |
| "Six patients with squamous cell carcinomas of the head and neck were given accelerated radiotherapy, carbogen breathing and high dose nicotinamide in order to evaluate the feasibility of this treatment regimen." | 1.29 | Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). ( Denekamp, J; Dennis, M; Franzén, L; Henriksson, R; Littbrand, B; Rojas, AM; Stratford, M; Zackrisson, B, 1994) |
| " It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects." | 1.29 | Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. ( Kaanders, JH; Marres, HA; Pop, LA; van Daal, WA; van der Kogel, AJ; van der Maazen, RW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.90) | 18.7374 |
| 1990's | 17 (16.19) | 18.2507 |
| 2000's | 15 (14.29) | 29.6817 |
| 2010's | 64 (60.95) | 24.3611 |
| 2020's | 7 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, MN | 1 |
| Tan, WS | 1 |
| Kichenadasse, G | 1 |
| Zhang, W | 1 |
| Jing, Y | 1 |
| Wang, S | 1 |
| Wu, Y | 1 |
| Sun, Y | 1 |
| Zhuang, J | 1 |
| Huang, X | 1 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Song, Y | 1 |
| Hu, Q | 1 |
| Ni, Y | 1 |
| Allen, NC | 1 |
| Martin, AJ | 6 |
| Snaidr, VA | 1 |
| Eggins, R | 1 |
| Chong, AH | 1 |
| Fernandéz-Peñas, P | 3 |
| Gin, D | 1 |
| Sidhu, S | 1 |
| Paddon, VL | 1 |
| Banney, LA | 1 |
| Lim, A | 1 |
| Upjohn, E | 1 |
| Schaider, H | 1 |
| Ganhewa, AD | 1 |
| Nguyen, J | 1 |
| McKenzie, CA | 4 |
| Prakash, S | 1 |
| McLean, C | 1 |
| Lochhead, A | 1 |
| Ibbetson, J | 1 |
| Dettrick, A | 1 |
| Landgren, A | 1 |
| Allnutt, KJ | 1 |
| Allison, C | 1 |
| Davenport, RB | 1 |
| Mumford, BP | 1 |
| Wong, B | 1 |
| Stagg, B | 1 |
| Tedman, A | 1 |
| Gribbin, H | 1 |
| Edwards, HA | 1 |
| De Rosa, N | 1 |
| Stewart, T | 1 |
| Doolan, BJ | 1 |
| Kok, Y | 1 |
| Simpson, K | 1 |
| Low, ZM | 1 |
| Kovitwanichkanont, T | 1 |
| Scolyer, RA | 4 |
| Dhillon, HM | 3 |
| Vardy, JL | 3 |
| Chadban, SJ | 1 |
| Bowen, DG | 1 |
| Chen, AC | 5 |
| Damian, DL | 8 |
| Tee, LY | 1 |
| Sultana, R | 1 |
| Tam, SYC | 1 |
| Oh, CC | 1 |
| Mateos-Mayo, A | 1 |
| Colmenero, I | 1 |
| Ramírez-Lluch, M | 1 |
| Martos-Cabrera, L | 1 |
| Hernández-Martín, Á | 1 |
| Torrelo, A | 1 |
| Arzeno, J | 1 |
| Leavitt, E | 1 |
| Lonowski, S | 1 |
| Kim, J | 1 |
| Knackstedt, TJ | 1 |
| Knackstedt, RW | 1 |
| Djohan, M | 1 |
| Djohan, R | 1 |
| Gastman, BR | 1 |
| Crowe, DR | 1 |
| Drago, F | 2 |
| Ciccarese, G | 2 |
| Cogorno, L | 1 |
| Calvi, C | 1 |
| Marsano, LA | 1 |
| Parodi, A | 2 |
| Minocha, R | 2 |
| Halliday, GM | 5 |
| Arenberger, P | 1 |
| Arenbergerova, M | 1 |
| Nestor, L | 1 |
| Clowry, J | 1 |
| Molloy, K | 1 |
| Connolly, M | 1 |
| Salim, A | 1 |
| Tobin, AM | 1 |
| Blomberg, M | 1 |
| He, SY | 1 |
| Harwood, C | 1 |
| Arron, ST | 1 |
| Demehri, S | 1 |
| Green, A | 1 |
| Asgari, MM | 1 |
| Gilmore, SJ | 1 |
| Lyons, JG | 1 |
| Madore, J | 1 |
| Rosenthal, A | 1 |
| Stoddard, M | 1 |
| Chipps, L | 1 |
| Herrmann, J | 1 |
| Jablonska, P | 1 |
| Mierzejewska, P | 1 |
| Kutryb-Zajac, B | 1 |
| Rzyman, W | 1 |
| Dziadziuszko, R | 1 |
| Polanska, J | 1 |
| Sitkiewicz, M | 1 |
| Smolenski, RT | 1 |
| Slominska, EM | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Breaker, K | 1 |
| Naam, M | 1 |
| La Rosa, FG | 1 |
| Flaig, IP | 1 |
| Flaig, TW | 1 |
| Mehta, S | 1 |
| Moon, J | 2 |
| Hashmi, M | 1 |
| Leblanc, M | 2 |
| Huang, CH | 2 |
| Rinehart, E | 1 |
| Wolf, GT | 2 |
| Urba, SG | 2 |
| Banerjee, SK | 1 |
| Williamson, S | 1 |
| El Tal, AK | 1 |
| Remichofsky, CJ | 1 |
| Mehregan, DA | 1 |
| Ganger, LK | 1 |
| Laban, S | 2 |
| Steinmeister, L | 2 |
| Gleißner, L | 2 |
| Grob, TJ | 1 |
| Grénman, R | 2 |
| Petersen, C | 2 |
| Gal, A | 1 |
| Knecht, R | 2 |
| Dikomey, E | 2 |
| Kriegs, M | 2 |
| Vin, H | 1 |
| Ching, G | 1 |
| Ojeda, SS | 1 |
| Adelmann, CH | 1 |
| Chitsazzadeh, V | 1 |
| Dwyer, DW | 1 |
| Ma, H | 1 |
| Ehrenreiter, K | 1 |
| Baccarini, M | 1 |
| Ruggieri, R | 1 |
| Curry, JL | 1 |
| Ciurea, AM | 1 |
| Duvic, M | 1 |
| Busaidy, NL | 1 |
| Tannir, NM | 3 |
| Tsai, KY | 1 |
| Bhatt, VR | 1 |
| Ganti, AK | 1 |
| Rademakers, SE | 2 |
| Hoogsteen, IJ | 3 |
| Rijken, PF | 2 |
| Terhaard, CH | 3 |
| Doornaert, PA | 3 |
| Langendijk, JA | 1 |
| van den Ende, P | 3 |
| van der Kogel, AJ | 7 |
| Bussink, J | 4 |
| Kaanders, JH | 8 |
| Huang, LY | 1 |
| Lee, YS | 1 |
| Huang, JJ | 1 |
| Chang, CC | 1 |
| Chang, JM | 1 |
| Chuang, SH | 1 |
| Kao, KJ | 1 |
| Tsai, YJ | 1 |
| Tsai, PY | 1 |
| Liu, CW | 1 |
| Lin, HS | 1 |
| Lau, JY | 1 |
| Holderfield, M | 1 |
| Nagel, TE | 1 |
| Stuart, DD | 1 |
| Liu, H | 1 |
| Wang, X | 1 |
| Shi, G | 1 |
| Jiang, L | 1 |
| Liu, X | 1 |
| Fathi, AT | 1 |
| Lin, WM | 1 |
| Durazzo, T | 1 |
| Piris, A | 2 |
| Sadrzadeh, H | 1 |
| Bernardo, L | 1 |
| Borger, DR | 1 |
| McAfee, SL | 1 |
| Kroshinsky, D | 1 |
| Chen, YB | 1 |
| Novello, S | 2 |
| Scagliotti, GV | 1 |
| Sydorenko, O | 1 |
| Vynnychenko, I | 1 |
| Volovat, C | 1 |
| Schneider, CP | 1 |
| Blackhall, F | 1 |
| McCoy, S | 1 |
| Hei, YJ | 1 |
| Spigel, DR | 1 |
| Huber, K | 1 |
| Feuchtinger, A | 1 |
| Borgmann, DM | 1 |
| Li, Z | 1 |
| Aichler, M | 1 |
| Hauck, SM | 1 |
| Zitzelsberger, H | 1 |
| Schwaiger, M | 1 |
| Keller, U | 1 |
| Walch, A | 1 |
| Lalami, Y | 1 |
| Garcia, C | 1 |
| Flamen, P | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Awada, A | 1 |
| Lin, CL | 1 |
| Chiang, WF | 1 |
| Tung, CL | 1 |
| Hsieh, JL | 1 |
| Hsiao, JR | 1 |
| Huang, WT | 1 |
| Feng, LY | 1 |
| Chang, CH | 1 |
| Liu, SY | 1 |
| Tsao, CJ | 1 |
| Feng, YH | 1 |
| Gilbert, J | 1 |
| Schell, MJ | 1 |
| Zhao, X | 1 |
| Murphy, B | 1 |
| Tanvetyanon, T | 1 |
| Leon, ME | 1 |
| Neil Hayes, D | 1 |
| Haigentz, M | 1 |
| Saba, N | 1 |
| Nieva, J | 1 |
| Bishop, J | 1 |
| Sidransky, D | 1 |
| Ravi, R | 1 |
| Bedi, A | 1 |
| Chung, CH | 1 |
| Aderhold, C | 1 |
| Faber, A | 1 |
| Umbreit, C | 1 |
| Birk, R | 1 |
| Weiss, C | 1 |
| Sommer, JU | 1 |
| Hörmann, K | 1 |
| Schultz, JD | 1 |
| Hsu, FT | 1 |
| Chang, B | 1 |
| Chen, JC | 1 |
| Chiang, IT | 1 |
| Liu, YC | 1 |
| Kwang, WK | 1 |
| Hwang, JJ | 1 |
| Choy, B | 1 |
| Dalziell, RA | 2 |
| Kricker, A | 1 |
| St George, G | 1 |
| Chinniah, N | 1 |
| Sidaway, P | 1 |
| Milosevic, MF | 1 |
| Townsley, CA | 1 |
| Chaudary, N | 1 |
| Clarke, B | 1 |
| Pintilie, M | 1 |
| Fan, S | 1 |
| Glicksman, R | 1 |
| Haider, M | 1 |
| Kim, S | 1 |
| MacKay, H | 1 |
| Yeung, I | 1 |
| Hill, RP | 1 |
| Fyles, A | 1 |
| Oza, AM | 1 |
| Schneider, TC | 1 |
| Kapiteijn, E | 1 |
| van Wezel, T | 1 |
| Smit, JWA | 1 |
| van der Hoeven, JJM | 1 |
| Morreau, H | 1 |
| Hajdenberg, J | 1 |
| Zhao, Y | 1 |
| Möckelmann, N | 1 |
| Rieckmann, T | 1 |
| Busch, CJ | 1 |
| Becker, B | 1 |
| Hoffer, K | 1 |
| Omniczynski, M | 1 |
| Rothkamm, K | 1 |
| Lowe, PM | 1 |
| Eris, JM | 1 |
| Bielski, VA | 1 |
| Escudero-Góngora, MM | 1 |
| Wu, X | 2 |
| Zhang, J | 1 |
| Yang, S | 1 |
| Kuang, Z | 1 |
| Tan, G | 1 |
| Yang, G | 1 |
| Wei, Q | 1 |
| Guo, Z | 1 |
| Affolter, A | 1 |
| Samosny, G | 1 |
| Heimes, AS | 1 |
| Schneider, J | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Sommer, K | 1 |
| Jensen, A | 1 |
| Mayer, A | 1 |
| Brenner, W | 1 |
| Mann, WJ | 1 |
| Brieger, J | 1 |
| Hong, DS | 1 |
| Reddy, SB | 1 |
| Prieto, VG | 2 |
| Wright, JJ | 1 |
| Cohen, PR | 1 |
| Diwan, AH | 1 |
| Evans, HL | 1 |
| Kurzrock, R | 1 |
| Arbiser, JL | 1 |
| Dubauskas, Z | 1 |
| Kunishige, J | 1 |
| Jonasch, E | 1 |
| Hwu, P | 1 |
| Arnault, JP | 2 |
| Wechsler, J | 2 |
| Escudier, B | 2 |
| Spatz, A | 2 |
| Tomasic, G | 2 |
| Sibaud, V | 1 |
| Aractingi, S | 1 |
| Grange, JD | 1 |
| Poirier-Colame, V | 1 |
| Malka, D | 2 |
| Soria, JC | 2 |
| Mateus, C | 2 |
| Robert, C | 3 |
| Smith, KJ | 1 |
| Haley, H | 1 |
| Hamza, S | 1 |
| Skelton, HG | 1 |
| Kwon, EJ | 1 |
| Kish, LS | 1 |
| Jaworsky, C | 1 |
| Masunaga, S | 7 |
| Hirayama, R | 1 |
| Uzawa, A | 1 |
| Kashino, G | 1 |
| Takata, T | 1 |
| Tanaka, H | 1 |
| Suzuki, M | 4 |
| Kinashi, Y | 4 |
| Liu, Y | 1 |
| Koike, S | 1 |
| Ando, K | 1 |
| Ono, K | 7 |
| Scagliotti, G | 1 |
| von Pawel, J | 1 |
| Reck, M | 1 |
| Pereira, JR | 1 |
| Thomas, M | 1 |
| Abrão Miziara, JE | 1 |
| Balint, B | 1 |
| De Marinis, F | 2 |
| Keller, A | 1 |
| Arén, O | 1 |
| Csollak, M | 1 |
| Albert, I | 1 |
| Barrios, CH | 1 |
| Grossi, F | 1 |
| Krzakowski, M | 1 |
| Cupit, L | 1 |
| Cihon, F | 1 |
| Dimatteo, S | 1 |
| Hanna, N | 1 |
| Smit, EF | 1 |
| Dingemans, AM | 1 |
| Thunnissen, FB | 1 |
| Hochstenbach, MM | 1 |
| van Suylen, RJ | 1 |
| Postmus, PE | 1 |
| Williamson, SK | 1 |
| Guaglianone, PP | 1 |
| Zhu, Y | 1 |
| Li, H | 1 |
| Yao, XD | 1 |
| Zhang, SL | 1 |
| Zhang, HL | 1 |
| Shi, GH | 1 |
| Yang, LF | 1 |
| Yang, ZY | 1 |
| Wang, CF | 1 |
| Ye, DW | 1 |
| Raymond, AK | 1 |
| Puri, PK | 1 |
| Selim, MA | 1 |
| Tyler, DS | 1 |
| Nelson, KC | 1 |
| Gridelli, C | 1 |
| Morgillo, F | 1 |
| Favaretto, A | 1 |
| Chella, A | 1 |
| Cerea, G | 1 |
| Mattioli, R | 1 |
| Tortora, G | 1 |
| Rossi, A | 1 |
| Fasano, M | 1 |
| Pasello, G | 1 |
| Ricciardi, S | 1 |
| Maione, P | 1 |
| Di Maio, M | 1 |
| Ciardiello, F | 1 |
| Donaldson, MR | 1 |
| Stetson, CL | 1 |
| Smith, JL | 1 |
| Janssens, GO | 2 |
| Bijl, HP | 2 |
| Chin, A | 2 |
| Pop, LA | 4 |
| Adnot-Desanlis, L | 1 |
| Bernard, P | 1 |
| Reguiaï, Z | 1 |
| Lynch, MC | 1 |
| Straub, R | 1 |
| Adams, DR | 1 |
| Force, J | 1 |
| Rajan, A | 1 |
| Dombi, E | 1 |
| Steinberg, SM | 1 |
| Giaccone, G | 1 |
| Bracarda, S | 1 |
| Ruggeri, EM | 1 |
| Monti, M | 1 |
| Merlano, M | 1 |
| D'Angelo, A | 1 |
| Ferraù, F | 1 |
| Cortesi, E | 1 |
| Santoro, A | 1 |
| Oberholzer, PA | 1 |
| Kee, D | 1 |
| Dziunycz, P | 1 |
| Sucker, A | 1 |
| Kamsukom, N | 1 |
| Jones, R | 1 |
| Roden, C | 1 |
| Chalk, CJ | 1 |
| Ardlie, K | 1 |
| Palescandolo, E | 1 |
| MacConaill, LE | 1 |
| Hofbauer, GF | 1 |
| McArthur, GA | 1 |
| Schadendorf, D | 1 |
| Garraway, LA | 1 |
| Hollville, E | 1 |
| Sarasin, A | 1 |
| Larcher, M | 1 |
| André, J | 1 |
| Kamsu-Kom, N | 1 |
| Boussemart, L | 1 |
| Lacroix, L | 1 |
| Eggermont, AM | 1 |
| Druillennec, S | 1 |
| Vagner, S | 1 |
| Eychène, A | 1 |
| Dumaz, N | 1 |
| Surjana, D | 1 |
| Moloney, FJ | 1 |
| Schirosi, L | 1 |
| Nannini, N | 1 |
| Nicoli, D | 1 |
| Cavazza, A | 1 |
| Valli, R | 1 |
| Buti, S | 1 |
| Garagnani, L | 1 |
| Sartori, G | 1 |
| Calabrese, F | 1 |
| Marchetti, A | 1 |
| Buttitta, F | 1 |
| Felicioni, L | 1 |
| Migaldi, M | 1 |
| Rea, F | 1 |
| Di Chiara, F | 1 |
| Mengoli, MC | 1 |
| Rossi, G | 1 |
| Peters, L | 1 |
| Rischin, D | 1 |
| Marres, HA | 6 |
| de Bree, R | 1 |
| Span, PN | 1 |
| Smavadati, S | 1 |
| Nordfjäll, K | 1 |
| Karlsson, K | 1 |
| Qvarnström, F | 1 |
| Simonsson, M | 1 |
| Bergqvist, M | 1 |
| Gryaznov, S | 1 |
| Ekman, S | 1 |
| Paulsson-Karlsson, Y | 1 |
| Wakelee, HA | 1 |
| Lee, JW | 1 |
| Hanna, NH | 1 |
| Traynor, AM | 1 |
| Carbone, DP | 1 |
| Schiller, JH | 1 |
| Tsao, AS | 1 |
| Liu, S | 1 |
| Lee, JJ | 1 |
| Alden, C | 1 |
| Blumenschein, G | 1 |
| Herbst, R | 1 |
| Davis, SE | 1 |
| Kim, E | 1 |
| Lippman, S | 1 |
| Stewart, D | 1 |
| Tang, XM | 1 |
| Wistuba, I | 1 |
| Hong, WK | 1 |
| Wijffels, KI | 2 |
| Ljungkvist, AS | 1 |
| van den Hoogen, FJ | 2 |
| de Wilde, PC | 2 |
| Raleigh, JA | 1 |
| Hoskin, PJ | 1 |
| Rojas, AM | 2 |
| Phillips, H | 1 |
| Saunders, MI | 1 |
| Merkx, MA | 2 |
| Jonathan, RA | 1 |
| Peeters, W | 1 |
| Oosterwijk, E | 1 |
| Polverino, A | 1 |
| Coxon, A | 1 |
| Starnes, C | 1 |
| Diaz, Z | 1 |
| DeMelfi, T | 1 |
| Wang, L | 1 |
| Bready, J | 1 |
| Estrada, J | 1 |
| Cattley, R | 1 |
| Kaufman, S | 1 |
| Chen, D | 1 |
| Gan, Y | 1 |
| Kumar, G | 1 |
| Meyer, J | 1 |
| Neervannan, S | 1 |
| Alva, G | 1 |
| Talvenheimo, J | 1 |
| Montestruque, S | 1 |
| Tasker, A | 1 |
| Patel, V | 1 |
| Radinsky, R | 1 |
| Kendall, R | 1 |
| Herbst, RS | 1 |
| Eichhorn, ME | 1 |
| Kleespies, A | 1 |
| Angele, MK | 1 |
| Jauch, KW | 1 |
| Bruns, CJ | 1 |
| Elser, C | 1 |
| Siu, LL | 1 |
| Winquist, E | 1 |
| Agulnik, M | 1 |
| Pond, GR | 1 |
| Chin, SF | 1 |
| Francis, P | 1 |
| Cheiken, R | 1 |
| Elting, J | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Petrenciuc, O | 1 |
| Chen, EX | 1 |
| Smid, L | 1 |
| Lesnicar, H | 1 |
| Zakotnik, B | 1 |
| Soba, E | 1 |
| Budihna, M | 1 |
| Furlan, L | 1 |
| Zargi, M | 1 |
| Rudolf, Z | 1 |
| Fenton, BM | 2 |
| Akuta, K | 4 |
| Akaboshi, M | 5 |
| Kawai, K | 3 |
| Takagaki, M | 4 |
| Abe, M | 5 |
| Boyce, DJ | 1 |
| Zackrisson, B | 1 |
| Franzén, L | 1 |
| Henriksson, R | 1 |
| Littbrand, B | 1 |
| Stratford, M | 1 |
| Dennis, M | 1 |
| Denekamp, J | 2 |
| Zheng, H | 1 |
| Olive, PL | 1 |
| van der Maazen, RW | 1 |
| van Daal, WA | 1 |
| Sakurai, Y | 1 |
| Kobayashi, T | 1 |
| Gensler, HL | 1 |
| Peters, JP | 1 |
| Hodgkiss, RJ | 1 |
| el-Said, A | 1 |
| Menke, D | 2 |
| Dorie, MJ | 1 |
| Brown, JM | 2 |
| Bernier, J | 1 |
| Rojas, A | 1 |
| Minatel, E | 1 |
| Horiot, J | 1 |
| Hamers, H | 1 |
| Antognoni, P | 1 |
| Dahl, O | 1 |
| Richaud, P | 1 |
| van Glabbeke, M | 1 |
| Piérart, M | 1 |
| Stone, HB | 1 |
| Minchinton, AI | 1 |
| Lemmon, M | 1 |
| Chaplin, DJ | 2 |
| Horsman, MR | 2 |
| Trotter, MJ | 2 |
| Overgaard, J | 1 |
| Christensen, KL | 1 |
| Carruthers, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.[NCT00460317] | Phase 3 | 1,450 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.) | ||
| Safety and Efficacy of Sequential Stereotactic Radiotherapy With S1 Combined With Endostar in the Treatment of Stage IV Lung Squamous Cell Carcinoma: Prospective, Multicenter, Exploratory Study[NCT04274270] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Not yet recruiting | |||
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)[NCT00300885] | Phase 3 | 926 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.) | ||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of response (PR or better) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). (NCT00300885)
Timeframe: Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
| Intervention | days (Median) |
|---|---|
| Sorafenib + C/P | 168 |
| Placebo + C/P | 134 |
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment. (NCT00300885)
Timeframe: Outcome measure was assessed every 3 weeks starting from randomization, during treatment period and every 3 months during follow-up period until death was recorded or up to data cutoff (1Oct2007) used for planned formal interim analysis
| Intervention | days (Median) |
|---|---|
| Sorafenib + C/P | 324 |
| Placebo + C/P | 322 |
PFS determined as time (days) from the date of randomization at start of study to disease progression (radiological or clinical) or death due to any cause, if death occurs before progression. (NCT00300885)
Timeframe: Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
| Intervention | days (Median) |
|---|---|
| Sorafenib + C/P | 139 |
| Placebo + C/P | 163 |
Best overall tumor response for the ITT population was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased). (NCT00300885)
Timeframe: Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not evaluated | Disease control | |
| Placebo + C/P | 1.1 | 22.9 | 47.8 | 17.5 | 10.6 | 56.3 |
| Sorafenib + C/P | 0.0 | 27.4 | 45.9 | 9.9 | 16.8 | 49.8 |
"Functional Assessment of Cancer Therapy - Lung cancer subscore (FACT-L). Patient reported outcome as assessed by FACT-L score. FACT-L questionnaire comprises statements about physical, social / family, emotional and functional well-being as well as additional concerns which have to be rated by the patients (0=not at all to 4=very much). Cycle duration defined as 21 days. Change from baseline in Total FACT-L on day 1 of cycles 3,5,7,9 (weeks 7,13,19 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation." (NCT00300885)
Timeframe: Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every other cycle (i.e. Cycle 3, 5, 7 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis
| Intervention | Scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | End of treatment (EOT) | |
| Placebo + C/P | 0.1 | -1.3 | -0.5 | -0.6 | -2.7 |
| Sorafenib + C/P | 0.0 | -1.4 | -0.8 | -1.2 | -3.1 |
Lung Cancer Symptoms (LCS) subscale ranges from 0 (severe debilitation) to 28 (asymptomatic). Cycle duration defined as 21 days. Change from baseline in LCS Subscale on day 1 of cycles 2 through 9 (weeks 4,7,10,13,16,19,22 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation. (NCT00300885)
Timeframe: Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every cycle (i.e. Cycle 2, 3, 4, 5 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis
| Intervention | Scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycle 6, Day 1 | Cycle 7, Day 1 | Cycle 8, Day 1 | Cycle 9, Day 1 | End of treatment (EOT) | |
| Placebo + C/P | -0.1 | -0.2 | -0.3 | -0.5 | -0.4 | -0.4 | -0.2 | -0.3 | -0.4 |
| Sorafenib + C/P | 0.0 | -0.4 | -0.6 | -0.6 | -0.8 | -0.8 | -1.2 | -0.9 | -0.9 |
14 reviews available for niacinamide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Niacinamide; | 2021 |
New Developments in the Management of Cutaneous Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoprevention; Chemotherapy, Adjuvant; Humans; Ly | 2021 |
Nicotinamide for skin cancer chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immune Tolerance; Keratosis, Ac | 2017 |
Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immunomodulation; Mela | 2018 |
New and current preventive treatment options in actinic keratosis.
Topics: Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Keratosis, Actinic; Male; Niacinamide | 2017 |
Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Health Behavior; Humans; Im | 2017 |
Skin cancer prevention: a review of current topical options complementary to sunscreens.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibit | 2019 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell | 2013 |
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melano | 2014 |
Nicotinamide: New Indications in Dermatology.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; Clinical Trials, Phase III as Topi | 2016 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease M | 2012 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; I | 2007 |
26 trials available for niacinamide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Topics: Antineoplastic Agents; Australia; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; | 2023 |
Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.
Topics: Carcinoma, Squamous Cell; Case-Control Studies; Female; Humans; Keratosis, Actinic; Kidney Transplan | 2017 |
Nicotinamide for prevention of nonmelanoma skin cancers: a change in practice?
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cost of Illness; Humans; Keratosis, Actinic; Niacin | 2017 |
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.
Topics: Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Count; Humans; Incidence; Macr | 2019 |
Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carb | 2015 |
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head a | 2016 |
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neopl | 2015 |
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Method | 2015 |
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; | 2016 |
A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Chemopreventio | 2016 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combine | 2011 |
Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Carbon Dioxide; Carcinoma, Squamous Cell; Deglut | 2012 |
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large | 2011 |
Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neopl | 2012 |
Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; | 2012 |
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexa | 2012 |
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic | 2002 |
Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 2005 |
Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell | 2006 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression | 2007 |
Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch | 1995 |
ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Topics: Adult; Aged; Carbon Dioxide; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Head and Neck | 2000 |
65 other studies available for niacinamide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Ag | 2021 |
Identification of Biological Functions and Prognostic Value of NNMT in Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Niacinamide; Nicotinamid | 2022 |
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib.
Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasm | 2021 |
Current Practices for Preventative Interventions for Nonmelanoma Skin Cancers Among Dermatologic Surgeons.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatologic Agents; Humans; Institution | 2021 |
Nicotinamide and skin cancer chemoprevention: The jury is still out.
Topics: Bayes Theorem; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; | 2018 |
Increased plasma concentration of 4-pyridone-3-carboxamide-1-ß-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies.
Topics: Aged; Arginine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Endothelial Cells; Female; Humans; Lung | 2019 |
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clin | 2013 |
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Se | 2013 |
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide | 2013 |
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Pheny | 2014 |
Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents; A | 2014 |
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Depend | 2014 |
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, | 2016 |
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; | 2014 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulati | 2015 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulati | 2015 |
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality | 2015 |
Skin cancer: Nicotinamide reduces new skin cancer risk.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati | 2016 |
ACP Journal Club. In high-risk patients, oral nicotinamide reduced number of new nonmelanoma skin cancers during treatment.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Prolifer | 2016 |
Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcino | 2017 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combin | 2017 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2008 |
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; B | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Hu | 2009 |
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2009 |
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoaca | 2009 |
The histologic spectrum of epithelial neoplasms induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2009 |
Influence of manipulating hypoxia in solid tumors on the radiation dose-rate effect in vivo, with reference to that in the quiescent cell population.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carbon Radioisotopes; Carcinoma, Squamous Cell; C | 2010 |
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulf | 2010 |
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; I | 2010 |
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes | 2010 |
Invasive squamous cell carcinoma and sorafenib in a black patient.
Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamo | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; C | 2011 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, S | 2011 |
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression | 2012 |
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcino | 2012 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumo | 2012 |
Elusive goal of targeting tumor hypoxia for therapeutic gain.
Topics: Carbon Dioxide; Carcinoma, Squamous Cell; Female; Humans; Laryngeal Neoplasms; Male; Niacinamide; Ox | 2012 |
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Topics: Carcinoma, Squamous Cell; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA, Neoplasm | 2012 |
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbon Dioxide; Carbonic Anhy | 2006 |
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Endothelium | 2006 |
The effects of carbogen and nicotinamide on intravascular oxyhaemoglobin saturations in SCCVII and KHT murine tumours.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Mice; Mice, Inbred C3H; Neo | 1995 |
Enhancement of chemosensitivity of quiescent cell populations in murine solid tumors using nicotinamide.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Cell Hypoxia; Cisplatin; Humans; Injections, Intra | 1994 |
Micro-regional mapping of HbO2 saturations and blood flow following nicotinamide administration.
Topics: Animals; Carcinoma, Squamous Cell; Mice; Mice, Inbred C3H; Niacinamide; Oxyhemoglobins; Regional Blo | 1994 |
Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
Topics: Administration, Inhalation; Aged; Carbon Dioxide; Carcinoma, Squamous Cell; Head and Neck Neoplasms; | 1994 |
The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumours.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Survival; Female; Mice; Mice, Inbred BALB C; | 1993 |
Radiosensitization of SCCVII tumours and normal tissues by nicotinamide and carbogen: analysis by micronucleus assay.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Therapy, C | 1993 |
Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; DNA Damage; DNA Repair; Dose-Response Relationship, | 1996 |
Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Ca | 1995 |
An attempt to enhance chemosensitivity of quiescent cell populations in solid tumors by combined treatment with nicotinamide and carbogen.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Carcinoma, Squamous Cell; C | 1996 |
Modification of the response of a quiescent cell population within a murine solid tumour to boron neutron capture irradiation: studies with nicotinamide and hyperthermia.
Topics: Animals; Borohydrides; Boron Compounds; Boron Neutron Capture Therapy; Carcinoma, Squamous Cell; Com | 1997 |
Augmentation in chemosensitivity of intratumor quiescent cells by combined treatment with nicotinamide and mild hyperthermia.
Topics: Animals; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Division; Cell Hypoxia; Cisplatin; Drug R | 1997 |
Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide.
Topics: Administration, Topical; Adoptive Transfer; Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cel | 1997 |
Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide.
Topics: Animals; Benzimidazoles; Blood Vessels; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Division; End | 1999 |
Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Survival; Chemotherapy, Adjuvant; Combined M | 1999 |
Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion.
Topics: Animals; Blood Pressure; Carcinoma, Squamous Cell; Female; Flavonoids; Hydralazine; Mice; Mice, Inbr | 1992 |
Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor.
Topics: Animals; Benzimidazoles; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Male; Mice; Mice, Inbred C3 | 1990 |
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy.
Topics: Animals; Benzimidazoles; Blood Pressure; Carcinoma, Squamous Cell; Cell Survival; Female; Fluorescen | 1989 |
Urocanic acid in epidermal carcinogenesis.
Topics: Animals; Carcinoma, Squamous Cell; Humans; Imidazoles; Methylcholanthrene; Mice; Neoplasms, Experime | 1968 |